CHAPTER 6

RECOMMENDATIONS

The Chlorthalidone, Ramipril & Alitretinoin were formulated as lipid formulation in an attempt to increase its dissolution & bioavailability. An optimized formulation containing these drugs was developed by estimating its solubility, indicative compatibility & drug release studies. Following oral administration in rats, lipid formulation provided significant increase in the bioavailability.

Any possible reduction in dosage amount without compromising the efficacy aspect will provide a commercial edge while marketing such product to prospective registered medical practitioners. The current development strategy is also expected prevent exposure to unintended healthy production personnel during manufacturing operation.

Overall, the current work has indicated that it is indeed possible to develop an effective & safely scalable formulation via a simple one-step process using basic laboratory equipment’s & procedures. Still, considering the limited sample size, the results are at best indicative & further clinical work can be undertaken to develop & commercially viable suprabioavailable format of Chlorthalidone, Ramipril & Alitretinoin formulations for human use.